Karolinska University Hospital
- Address
- Norrbacka S3 02, 171 76 Stockholm, Sweden
Immune System Diseases
The dermatology department at Karolinska University Hospital is advancing treatments for immune‑mediated skin conditions, focusing on innovative therapies that target underlying inflammatory pathways.
- Evaluation of a JAK inhibitor combined with topical corticosteroids for moderate to severe eczema
- Long‑term safety monitoring of the same JAK inhibitor in adolescents and adults
- Assessment of an IL‑13 targeting monoclonal antibody for hand eczema
- Exploration of immune modulation strategies to improve patient outcomes
These studies aim to enhance symptom control, reduce reliance on systemic drugs, and provide durable relief for patients with chronic immune skin diseases.
Neoplasms
Research in the oncology spectrum includes trials for both pediatric blood cancers and advanced solid tumors with specific genetic features, seeking to boost survival and personalize therapy.
- Improving event‑free survival in infants with KMT2A‑rearranged acute lymphoblastic leukemia
- Targeted treatment of microsatellite instability‑high or mismatch repair deficient metastatic tumors
- Integration of DNA alteration profiling to guide therapeutic choices
- Evaluation of long‑term outcomes in high‑risk pediatric leukemia
The goal is to refine treatment protocols and offer effective options for patients facing aggressive or genetically defined cancers.
Skin and Connective Tissue Diseases
The unit concentrates on severe dermatologic disorders, employing novel agents to lessen disease burden and improve quality of life for individuals with chronic skin conditions.
- Reduction of disease severity in atopic dermatitis through new therapeutic approaches
- Management of moderate‑to‑severe hand eczema with targeted biologics
- Development of biomarkers to track skin inflammation
- Assessment of patient‑reported outcomes to gauge treatment impact
By linking clinical care with research, the department strives to bring cutting‑edge treatments from the lab to the bedside.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Karolinska University Hospital
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Jan 2019 | — |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Hydrocortisone | 3 | Unknown | 2019-01-02 | 2024-10-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.